Skip to main content
OpenTrials
Completed

NCT Number: NCT02493998

A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B) is a severe neurodegenerative disorder. The purpose of this study is to learn more about the health problems in patients with MPS IIIB and how to measure these problems over time. It will particularly look at how the disease develops in young children. This is an observational study, so no experimental drug will be given. The results from this study will help us design future studies to measure whether these health problems get better when we give experimental drug for MPS IIIB.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mucopolysaccharidosis Type IIIB Carbohydrate Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Genetic Diseases, Inborn Lysosomal Storage Diseases MPS 3 B MPS III B Metabolic Diseases Metabolism, Inborn Errors Mucinoses Mucopolysaccharidoses Mucopolysaccharidosis III Mucopolysaccharidosis Type 3 B Nutritional and Metabolic Diseases Skin and Connective Tissue Diseases

Age range

1 year–10 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Melbourne Children's Trials Centre, Melbourne, Victoria, Australia

Loading trial locations.

About this study

This is a multicenter, multinational, longitudinal, observational study in subjects 1 through 10 years of age who have been diagnosed with MPS IIIB. Data will be prospectively collected from 20 to 30 subjects to understand the clinical progression of MPS IIIB in terms of neurocognitive function, behavior, quality of life, imaging characteristics, genotype, and biochemical markers of disease burden. This information may help inform the design and interpretation of subsequent interventional studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals eligible to participate in this study must meet all of the following criteria:
  • Has deficient NAGLU enzyme activity at Screening. Blood for NAGLU enzyme activity will be collected and analyzed centrally.
  • Is ≥ 1 and ≤ 10 years of age and has an age-equivalent of ≥ 12 months on the VABS-II
  • DQ ≥ 50 (determined by BSID-III or KABC-II)
  • Has presented with signs/symptoms consistent with MPS IIIB; for individuals who have not presented with signs/symptoms of disease (e.g., siblings of known patients), the determination of eligibility will be at the discretion of the BioMarin medical monitor in conjunction with the site investigator.
  • Written informed consent from parent or legal guardian and assent from subject, if required
  • Has the ability to comply with protocol requirements, in the opinion of the investigator

Exclusion criteria

  • Has another neurological illness that may have caused cognitive decline (e.g., trauma, meningitis, or hemorrhage) before study entry
  • Requires ventilation support, except for noninvasive support at night
  • Has received stem cell, gene therapy or ERT for MPS IIIB
  • Has contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities)
  • Has contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, or aneurysm clip in the brain)
  • Has a history of poorly controlled seizure disorder
  • Is prone to complications from intraventricular drug administration, including patients with hydrocephalus or ventricular shunts
  • Has received any investigational medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
  • Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's wellbeing or safety, or the interpretability of the subject's clinical data.

Treatment and study plan

Primary outcomes

  1. Neurocognitive function

    Time frame: Screening, baseline, and every 12 weeks, for up to 48-96 weeks

    A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.

  2. Imaging characteristics

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

    MRI will be used to assess changes in size of various organs affected by the disease, including brain, liver and spleen.

  3. Behavioral function

    Time frame: Baseline and every 12 weeks, for up to 48-96 weeks

    Disease-related behaviors will be assessed using an MPS III-specific behavior rating scale.

  4. Hearing

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

    The function of conductive and sensorineural hearing pathways will be assessed using tympanometry and auditory brainstem response (ABR).

  5. Sleep habits

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

    Patient sleep habits will be assessed using specific questionnaires.

  6. Quality-of-life

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

    Multiple QOL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.

  7. Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden

    Time frame: Baseline and every 24 weeks, for up to 48-96 weeks

    Blood, urine, and CSF samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.

Sponsors and collaborators

Lead sponsor

Allievex Corporation

Industry

Registry information

Official study title

A Prospective, Observational Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jul 10, 2015
Registry last updated
Mar 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.